{"url_path":"/sec/coll/8-k/2026-06-30/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1267565/0001104659-26-079323-index.html","accession_number":"0001104659-26-079323","cik":"0001267565","ticker":"COLL","issuer_name":"COLLEGIUM PHARMACEUTICAL, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1267565/0001104659-26-079323-index.html","primary_entity_key":"0001267565","primary_entity_name":"COLLEGIUM PHARMACEUTICAL, INC"},"word_count":767,"has_tables":true,"body_markdown":"false\n0001267565\n\n0001267565\n\n2026-05-12\n2026-05-12\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K/A**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event\nreported): **May 12, 2026**\n\n \n\n**COLLEGIUM PHARMACEUTICAL, INC.**\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n**Virginia**\n \n**001-37372**\n \n**03-0416362**\n\n(State\nor Other Jurisdiction\n\nof Incorporation or Organization)\n \n(Commission\nFile Number)\n \n(IRS Employer Identification\n\nNo.)\n\n \n\n**100 Technology Center Drive**\n\n**Suite 300**\n\n**Stoughton, MA** **02072**\n\n(Address of principal executive offices) (Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(781) 713-3699**\n\n  \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of\neach class**\n**Trading Symbol(s)**\n**Name of each\nexchange on which registered**\n\nCommon stock, par value $0.001 per share\nCOLL\nThe NASDAQ Global Select Market\n\n \n\nCheck the appropriate box below if the\nForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions\n(see General Instruction A.2. below):\n\n \n\n¨ \nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨ \nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨  Pre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨ \nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging\ngrowth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any\nnew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Explanatory Note**\n\n \n\nOn May 12, 2026, Collegium Pharmaceutical, Inc.\n(the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “Original Form 8-K”),\nreporting among other items, that the Company completed the previously announced acquisition (the “Closing”) of (i) all\nof the issued and outstanding limited liability interests of GPC Commave Holding, LLC, a Delaware limited liability company (“GPC”),\nfrom Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“Corium” or “Commave Seller”), and\n(ii) all of the issued and outstanding limited liability interests of Commave Sub, LLC, a Delaware limited liability company, from\nCorium, LLC, a Delaware limited liability company (“Corium Seller” and together with Commave Seller, the “Seller Parties”),\npursuant to an Equity Purchase Agreement (the “Purchase Agreement”), by and among the Company and Seller Parties, dated March 19,\n2026. Upon the Closing, the Company acquired AZSTARYS®, a central nervous system stimulant prescription medicine used for the treatment\nof Attention-Deficit/Hyperactivity Disorder, in people 6 years of age and older (the “Acquisition”).\n\n \n\nThe aggregate consideration paid by the Company\nat the Closing pursuant to the Purchase Agreement was approximately $655.6 million in cash (following customary adjustments for net working\ncapital, indebtedness, cash, and transaction expenses), which was funded by approximately $355.6 million of the Company’s existing\ncash on hand and $300.0 million from a delayed draw term loan which is part of the Credit Agreement the Company entered into in December 2025.\nThe Company may also pay Commave Seller up to $135 million in additional consideration if AZSTARYS achieves certain future commercial\nand manufacturing milestones.\n\n \n\nThe Company is filing this amendment to the Original\n8-K (this “Form 8-K/A”) to amend and supplement the Original 8-K to include historical financial statements of Corium\nand pro forma financial information as required by Items 9.01(a) and 9.01(b), respectively, of Form 8-K that were excluded from\nthe Original 8-K in reliance on the instructions to such items. Except as noted in this paragraph, no other information contained in the\nOriginal 8-K is amended or supplemented. This Form 8-K/A should be read together with the Original 8-K.\n\n \n\nThe historical financial statements of Corium included\nunder Item 9.01(a) are on a consolidated basis, which includes both AZSTARYS and ADLARITY®, an FDA-approved Alzheimer’s\nproduct that was not part of the Acquisition and is no longer actively commercialized by the Seller Parties. The Company did not acquire\nADLARITY. AZSTARYS constituted substantially all of Corium’s consolidated operations, and accordingly Corium’s consolidated\nfinancial statements are presented pursuant to Rule 3-05 of Regulation S-X.\n\n \n\nThe unaudited pro forma financial information included\nin Item 9.01(b) reflects the acquisition of AZSTARYS only. The results, assets, and liabilities of ADLARITY have been excluded from\nthe pro forma financial information, as further described in the notes thereto."}